Related Experiment Video
Updated: Jan 14, 2026
Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System
Published on: October 26, 2010
Role of 5-Hydroxydecanoate in the Neuroprotective Activity of Diosmetin Against Rotenone-Induced Dopaminergic
Krishna Kumar Varshney1, Jeetendra Kumar Gupta1, Rajnish Srivastava2
1Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
Introduction:
The present study aims to compare the monotherapy of diosmetin and 5- hydroxydecanoate (5-HD) against the therapeutic effect of their combination therapy in the unilaterally injected rotenone-induced neurotoxicity in the male rats. Motor deficits accompany Parkinson's Disease (PD), while Bioflavonoids like diosmetin, which are antioxidants and anti-inflammatories, protect against neurotoxins. Moreover, mitochondrial dysfunction contributes to PD. The mitochondrial ATP-sensitive potassium channel [mito(KATP)] regulates reactive species and 5-HD, meaning decreasing it may lessen mitochondrial injury. To evaluate the effect of diosmetin, alone and in combination with 5-HD, on Oxidative Stress (OS) markers, mitochondrial function, and dopaminergic preservation in the SNpc.
Methods:
Male Wistar rats were divided into seven groups, including normal control, sham, rotenone-treated, and treatment groups receiving diosmetin, 5-HD, their combination, or selegiline as a standard drug. Biochemical assays were conducted to assess OS markers, mitochondrial complex- I activity, and dopaminergic neuroprotection. Behavioral tests were performed to evaluate motor deficits.
Results:
Rotenone administration significantly increased OS, impaired mitochondrial complex-I activity, and reduced motor coordination. Diosmetin treatment significantly reverses the effects of rotenone. Combined treatment with diosmetin and 5-HD showed enhanced neuroprotective effects compared to individual treatments.
Discussion:
This study demonstrates that both diosmetin and 5-HD monotherapies alleviate rotenone-induced behavioral impairments in the experimental rats. Additionally, the individual treatment of diosmetin and 5-HD reduces dopaminergic toxicity induced by rotenone. At the sub-- cellular level, diosmetin and 5-HD monotherapies counteract rotenone's impact on antioxidant markers, DA metabolites, and mitochondrial function in the SNpc region of the brain. Notably, combining diosmetin and 5-HD yielded superior therapeutic effects on rotenone-induced behavioral and molecular changes compared to either monotherapy alone. These findings suggest that diosmetin and 5-HD may offer a promising alternative for PD management.
Conclusion:
Diosmetin exhibits potent antioxidant and neuroprotective properties against rotenone-induced PD-like pathology. The combination of diosmetin and 5-HD offers a synergistic therapeutic potential, suggesting a promising approach for managing oxidative stress and mitochondrial dysfunction in PD.
Insights
The combination of diosmetin and 5-hydroxydecanoate (5-HD) shows enhanced neuroprotection against Parkinson's Disease-like pathology in rats. This synergistic approach effectively combats oxidative stress and mitochondrial dysfunction, offering a promising treatment strategy.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's Disease (PD) is characterized by motor deficits and neurodegeneration.
- Oxidative stress and mitochondrial dysfunction are key contributors to PD pathogenesis.
- Diosmetin, a bioflavonoid, possesses antioxidant and anti-inflammatory properties.
- 5-hydroxydecanoate (5-HD) influences mitochondrial function by modulating ATP-sensitive potassium channels.
Purpose of the Study:
- To compare the efficacy of diosmetin and 5-HD monotherapy versus their combination therapy in a rotenone-induced rat model of Parkinson's Disease.
- To evaluate the neuroprotective effects of diosmetin and 5-HD on oxidative stress, mitochondrial function, and dopaminergic neuron preservation.
- To assess the impact of these treatments on motor deficits associated with Parkinson's Disease.
Main Methods:
- Male Wistar rats were divided into control, rotenone-treated, and treatment groups (diosmetin, 5-HD, combination, selegiline).
- Neurotoxicity was induced using unilateral rotenone injection.
- Biochemical assays measured oxidative stress markers and mitochondrial complex-I activity.
- Behavioral tests assessed motor coordination and deficits.
Main Results:
- Rotenone administration induced significant oxidative stress, impaired mitochondrial function, and motor deficits.
- Both diosmetin and 5-HD monotherapy partially reversed rotenone-induced neurotoxicity.
- The combination therapy of diosmetin and 5-HD demonstrated significantly enhanced neuroprotective effects compared to monotherapies.
- Combined treatment improved antioxidant markers, dopaminergic neuron survival, and mitochondrial function more effectively than individual treatments.
Conclusions:
- Diosmetin and 5-HD monotherapies provide neuroprotection against rotenone-induced Parkinson's Disease-like pathology.
- The combination of diosmetin and 5-HD exhibits synergistic therapeutic potential, offering superior benefits.
- This combination therapy represents a promising strategy for managing oxidative stress and mitochondrial dysfunction in Parkinson's Disease.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...